Chitosomes-In-Chitosan Hydrogel for Acute Skin Injuries: Prevention and Infection Control.
Lisa Myrseth HemmingsenKjersti JulinLuqman AhsanPurusotam BasnetMona JohannessenNataša Škalko-BasnetPublished in: Marine drugs (2021)
Burns and other skin injuries are growing concerns as well as challenges in an era of antimicrobial resistance. Novel treatment options to improve the prevention and eradication of infectious skin biofilm-producing pathogens, while enhancing wound healing, are urgently needed for the timely treatment of infection-prone injuries. Treatment of acute skin injuries requires tailoring of formulation to assure both proper skin retention and the appropriate release of incorporated antimicrobials. The challenge remains to formulate antimicrobials with low water solubility, which often requires carriers as the primary vehicle, followed by a secondary skin-friendly vehicle. We focused on widely used chlorhexidine formulated in the chitosan-infused nanocarriers, chitosomes, incorporated into chitosan hydrogel for improved treatment of skin injuries. To prove our hypothesis, lipid nanocarriers and chitosan-comprising nanocarriers (≈250 nm) with membrane-active antimicrobial chlorhexidine were optimized and incorporated into chitosan hydrogel. The biological and antibacterial effects of both vesicles and a vesicles-in-hydrogel system were evaluated. The chitosomes-in-chitosan hydrogel formulation demonstrated promising physical properties and were proven safe. Additionally, the chitosan-based systems, both chitosomes and chitosan hydrogel, showed an improved antimicrobial effect against S. aureus and S. epidermidis compared to the formulations without chitosan. The novel formulation could serve as a foundation for infection prevention and bacterial eradication in acute wounds.
Keyphrases
- wound healing
- drug delivery
- antimicrobial resistance
- cancer therapy
- staphylococcus aureus
- hyaluronic acid
- drug release
- pseudomonas aeruginosa
- soft tissue
- photodynamic therapy
- drug induced
- cystic fibrosis
- hepatitis b virus
- helicobacter pylori infection
- multidrug resistant
- replacement therapy
- acute respiratory distress syndrome